ClinicalTrials.gg
CompletedNCT06280703Updated Oct 6, 2026

A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)

A Phase 1 interventional study of LY3938577 and Placebo in Healthy and Type 1 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Updated Oct 6, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.

Enrollment
14th of 69
121 · median 38
Started
2024
with 2 others
Phase 1
22 of 69
none open now
Registered
67th of 69
by date
Lead sponsor
31 of 69
Eli Lilly and Company

Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 14th largest by enrollment, is one of 3 that started in 2024, is one of 22 in phase 1, and was the 67th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it. At a later stage of this study (part B and C) the blood sugar lowering effect and the duration of action of LY3938577 will be evaluated compared to Insulin Degludec.

The study will also evaluate the safety and tolerability of LY3938577 and information about any side effects experienced will be collected.

The study will be conducted in four parts (A, B, C, and D). Healthy participants in Part A Period 1 will receive a single dose of LY3938577 or a placebo given via intravenous (IV) infusion. In Part A Period 2, participants will receive a single subcutaneous (SC) dose of either LY3938577 or placebo. Participants in Part B with Type 1 Diabetes Mellitus (T1DM) will receive single doses of either LY3938577 or Insulin Degludec given via IV infusion. Participants in Part C with Type 1 Diabetes Mellitus (T1DM) will receive two doses of either LY3938577 or Insulin Degludec administered SC. Participants in Part D with Type 1 Diabetes Mellitus (T1DM) will be evaluated in 2 periods, with Period 1 administered pre-study basal insulin and lispro mealtime insulin to establish insulin needs, and Period 2 administered lispro mealtime insulin and daily doses of LY3938577.

The study will last up to approximately 11 weeks for Part A, 10 weeks for Part B, 13 weeks for Part C, and 10 weeks for Part D , including screening period.

03

Conditions studied

  • Healthy
  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A -

  • Participants who are overtly healthy as determined by medical history and physical examination.

Parts B and C -

  • Have Type 1 Diabetes Mellitus (T1DM) for at least 2 years with a fasting C-peptide level of 0.20 Nanomoles Per Liter (nmol/L) or less, or nonfasting C-peptide level of 0.30 nmol/L or less at screening.
  • Have well-controlled between 6.0% to 8.5 percent (%).
  • Insulin pump users with a total daily basal dose between 15 to 45 International Unit (IU).

Part D -

  • Have T1DM for at least 1 year with a fasting C-peptide level of 0.20 nmol/L or less, or non-fasting C-peptide level of 0.30 nmol/L or less.
  • HbA1c between 6% to 8.5% inclusive.
  • Insulin pump users with a total daily basal dose between 15 to 45 International Unit (IU).
  • Insulin multiple daily injection users (glargine or degludec insulin) with a total daily insulin dose between 0.3 to \<1.2 (I)U/kg/day.
  • No hypoglycaemia unawareness.
  • Basal insulin dose that is between 30% to 70% of the total daily insulin dose
  • Are able to complete the exercise challenge test.

All Parts -

  • Have normal blood pressure, pulse rate and safety laboratory test results that are acceptable for the study.
  • Have (BMI) between 18.0 and 35.0 kilograms per meter squared (kg/m²), inclusive, at screening.
  • Have venous access sufficient to allow for blood sampling.
  • Male and/or female not of .

Exclusion criteria

Exclusion Criteria:

Parts B, C, and D -

  • Have had more than 1 emergency room visit or hospitalization due to poor glucose control (hyperglycemia or diabetic ketoacidosis) within the last 6 months prior to screening.
  • Have had any episodes of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia), hypoglycemia unawareness, or both within the last 6 months prior to screening.

Parts B and C -

  • Have been treated with Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA), Dipeptidyl Peptidase 4 (DPP4) inhibitor, Glucose-dependent Insulinotropic Polypeptide (GIP) agonists, Metformin, or Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors within the previous 3 months.
  • Have received systemic or inhaled therapy (excluding topical, intraarticular, and intraocular preparations) for more than 14 consecutive days within 4 weeks before screening.

Part D -

  • Have been treated with Dipeptidyl peptidase-4 (DPP-IV) inhibitors, GLP-1 RA, GIP/GLP-1 RA, Metformin, Pramlintide, SGLT2 inhibitors, or Neutral Protamine Hagedorn (NPH) insulin within the previous 3 months.

All Parts -

  • Have had any of the following cardiovascular conditions: acute myocardial infarction, Class III or IV heart failure, or cerebrovascular accident (stroke).
  • Have gastroparesis or have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery (for example, Lap-Band®) prior to screening.
  • Have history of renal transplantation, currently receiving renal dialysis, have serum creatinine level of more than 2.00 milligrams per decilitre (mg/dL) or have an estimated of less than 60.0 milliliters (mL) / minute /1.73 square meters.
  • Have acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease except non-alcoholic fatty liver disease (that is, participants with non-alcoholic fatty liver disease are eligible for participation), and/or have elevated liver enzyme measurements, as determined by the local laboratory at screening and as indicated:

    • Total (TBL) >2 × the (ULN) in the absence of Gilbert's syndrome, or
    • (ALT) /serum glutamic pyruvic transaminase (SGPT) >2.5 × ULN, or
    • Aspartate aminotransferase (AST) /serum glutamic oxaloacetic transaminase (SGOT) >2.5 × ULN.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Part A Period 1: LY3938577

    Single dose of LY3938577 administered intravenously (IV) in healthy participants.

    Drug: LY3938577

  • Placebo comparator
    Part A Period 1: Placebo

    Single dose of Placebo administered intravenously (IV) in healthy participants.

    Drug: Placebo

  • Experimental
    Part B: LY3938577

    For each euglycemic and hyperglycemic clamps participants with T1DM will receive single doses of LY3938577 administered intravenously with Insulin Lispro administered at a constant low rate to cover individual participant's basal (fasting) insulin demand to maintain a stable glucose level.

    Drug: LY3938577 · Drug: Insulin Lispro

  • Active comparator
    Part B: Insulin Degludec

    For each euglycemic and hyperglycemic clamps participants with T1DM will receive single doses of Insulin Degludec administered intravenously with Insulin Lispro administered at a constant low rate to cover individual participant's basal (fasting) insulin demand to maintain a stable glucose level.

    Drug: Insulin Degludec · Drug: Insulin Lispro

  • Experimental
    Part C: LY3938577

    LY3938577 administered subcutaneously (SC)

    Drug: LY3938577

  • Active comparator
    Part C: Insulin Degludec

    Insulin Degludec administered subcutaneously (SC)

    Drug: Insulin Degludec

  • Experimental
    Part A Period 2: LY3938577

    Sequential dose of LY3938577 administered subcutaneously (SC).

    Drug: LY3938577

  • Placebo comparator
    Part A Period 2: Placebo

    Sequential dose of Placebo administered subcutaneously (SC)

    Drug: Placebo

  • Other
    Part D Period 1: Basal Insulin and Lispro Prandial Insulin

    Pre-study basal insulin (provided by patient) and lispro prandial insulin administered SC

    Drug: Basal Insulin · Drug: Lispro Prandial Insulin

  • Experimental
    Part D Period 2: Lispro Prandial Insulin and LY3938577

    Lispro prandial insulin and LY3938577 administered SC

    Drug: LY3938577 · Drug: Lispro Prandial Insulin

Interventions

  • Administered Intravenously (IV)

  • DrugPlacebo

    Administered Intravenously (IV)

  • Administered Intravenously (IV)

  • Administered Intravenously (IV)

  • Administered subcutaneously (SC)

  • DrugPlacebo

    Administered subcutaneously (SC)

  • Administered SC

  • DrugBasal Insulin

    Administered subcutaneously (SC)

  • DrugLispro Prandial Insulin

    Administered subcutaneously (SC)

06

What researchers measure

Primary outcomes

  1. Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration.

    A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Baseline up to Approximately Week 11

  2. Part B and D: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration.

    A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Baseline up to Week 10

  3. Part A: Number of Participants With Clinically Significant Changes in Vital Signs

    Time frame: Baseline up to Approximately Week 11

  4. Part B: Number of Participants With Clinically Significant Changes in Vital Signs

    Time frame: Baseline up to Week 10

  5. Part A: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters

    Time frame: Baseline up to Approximately Week 11

  6. Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters

    Time frame: Baseline up to Week 10

  7. Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577

    PK: AUC of LY3938577 for intravenous administration

    Time frame: Predose on day 1 up to week 13 post dose

  8. Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577

    PK: AUC of LY3938577 for SC administration

    Time frame: Predose on day 1 up to week 13 post dose

  9. Part B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577

    PK: AUC of LY3938577

    Time frame: Predose on day 1 up to week 13 post dose

  10. Part C: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577

    PK: AUC of LY3938577 for SC administration

    Time frame: Predose on day 1 up to week 13 post dose

  11. Part D: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577

    PK: AUC of LY3938577 for SC administration

    Time frame: Predose on day 1 up to week 13 post dose

  12. Part A: PK: Maximum Observed Concentration (Cmax) of LY3938577

    PK: Cmax of LY3938577

    Time frame: Predose on day 1 up to week 13 post dose

  13. Part B: PK: Maximum Observed Concentration (Cmax) of LY3938577

    PK: Cmax of LY3938577

    Time frame: Predose on day 1 up to week 13 post dose

  14. Part C: PK: Concentration of LY3938577

    Time frame: Predose on day 1 up to week 13 post dose

Secondary outcomes

  1. Part B: Pharmacodynamic (PD): Area under the glucose infusion rate curve (GIR AUC) of LY3938577

    Measured at different glucose levels in participants with T1DM

    Time frame: Predose up to day 14 post dose

  2. Part C: PD: Glucose infusion rate (GIR) of LY3938577

    Measured at different glucose levels in participants with T1DM

    Time frame: Predose up to day 14 post dose

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung
    Neuss, 41460, Germany
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Oct 2026, 28 months.

Of 98 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 28 months is above that.

Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Feb 28, 2024
StartActual
May 15, 2024
Primary completionActual
Oct 3, 2026was Sep 2026
CompletionActual
Oct 3, 2026was Sep 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 6, 2026
Primary completion
Sep 2026→Oct 3, 2026 (actual)
Oct 6, 2026
Study completion
Sep 2026→Oct 3, 2026 (actual)
Oct 6, 2026
Enrollment
118 (estimated)→121 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Completed
    Primary completion Sep 2026→Oct 3, 2026 (now actual)
    Study completion Sep 2026→Oct 3, 2026 (now actual)
    Enrollment 118 (estimated)→121 (actual)
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06280703
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
May 15, 2024
Primary completion
Oct 3, 2026
Completion
Oct 3, 2026
Last update
Oct 6, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: LY3938577 · Insulin Lispro

Start the discussion